Sunshine Biopharma is set to bolster its portfolio by more than 50 products, while adding more than CAD10m to its top line, after snapping up its fellow Canadian firm Nora Pharma.
Sunshine Biopharma feels it has a “solid position in the generic prescription drugs industry,” and is “closer to our objective of becoming a fully-integrated pharma company,” after completing its acquisition of fellow Canadian firm Nora Pharma.
Montreal-based Sunshine Biopharma has paid CAD30m ($21.9m) for its rival company, in a combination of cash, the firm’s common stock...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
